MARKET WIREYahoo Finance • 17h ago
Lisata Therapeutics wins new US patent for pancreatic cancer drugYahoo Finance report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
Why LSTA Stock advanced +0.99% Today — RQD Quant Desk Flash
$1.02 +0.99% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.02
Lisata Therapeutics Inc. (LSTA) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $11.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on LSTA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is LSTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Lisata Therapeutics Inc. (NASDAQ: LSTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.02 (+0.99% 1D, market cap $11.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LSTA ranks #849 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does LSTA compare to GTBP and GDTC in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LSTA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GTBP (GT Biopharma Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $11.0M) and GDTC (CytoMed Therapeutics Limited) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, LSTA leads on earnings multiple (N/A) while LSTA leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for LSTA?
▼
Per LSTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000320017), Lisata Therapeutics Inc. generated $170.0K in revenue (-83.0% YoY), -$17.0M in net income, and -$16.0M in free cash flow against $17.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.02 (-0.01%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LSTA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY LSTA SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (28% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.08-3.7% Next Q
37
Q2 (-2Q)Grade E$1.04-1.9% Next Q
34
Q3 (-1Q)Grade E$1.02+0% Next Q
32
CurrentGrade E$1.02-9.8% Hist 90D α
29
Trajectory: E (37) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a LSTA Turnaround Squeeze
While LSTA currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.37) and Max Pain ($1.07) forces dealer call-delta covering toward $5.32.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $LSTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LSTA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why LSTA Stock advanced +0.99% Today — RQD Quant Desk Flash
Lisata Therapeutics Inc. (LSTA) advanced +0.99% to $1.02, trading at 2% of its 52-week range ($0.96 – $5.07). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.96 – $5.07) with RSI-14 at 39.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.02 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live LSTA Headlines & Catalysts
MARKET WIREStocktwits • 20h ago
Lisata Therapeutics Inc (LSTA) sentiment score, message volume, participation score and buzz levelStocktwits report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 23h ago
LISATA THERAPEUTICS, INC. SEC Filing (Oct 19, 2026)Stock Titan report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGlobeNewswire • 1d ago
Lisata Therapeutics Announces New Method of Use PatentGlobeNewswire report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Lisata Therapeutics, Inc. (LSTA) Stock Price, News, Quote & HistoryYahoo Finance report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Daily Tribune News • 1d ago
Halper Sadeh LLC is Investigating Whether BWIN, LSTA, ACVA are Obtaining Fair Deals for their ShareholdersThe Daily Tribune News report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Manila Times • 1d ago
Lisata Therapeutics Appoints Jeff Farrow to Board of DirectorsThe Manila Times report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGlobeNewswire • 1d ago
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of AcromegalyGlobeNewswire report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 18d ago
Lisata adds biopharma finance veteran Jeffrey Farrow to boardLisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said it has appointed Jeffrey Farrow, a veteran biopharma finance executive, to its board of directors. Farrow fills a newly created seat, expanding the board from seven to
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LSTA)
- ✓Walkthrough of LSTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
LSTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -69.55%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.01H $1.02L $1.01C $1.02VOL 60.8K
RES: $1.62SUP: $0.96SMA50: $1.37SMA200: $2.98
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LSTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on LSTA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for LSTA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LSTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LSTA)
Health Care Rank #849 of 1016
⚔️ GTBP vs LSTA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (LSTA vs. GTBP, GDTC, ASBP, CLRB)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Lisata Therapeutics Inc. (LSTA) ranks #849 by composite RQD confidence (29/100, grade E) and #885 by equity capitalization ($11.0M). Within this direct 5-issuer industry benchmark cohort, LSTA leads on earnings valuation at N/A trailing P/E, while LSTA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GDTC currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with LSTA at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LSTA
ACTIVE
Lisata Therapeutics Inc. | E | 29/100 | — | — | -35.0% | +0.99% | $11.0M | Benchmark Subject |
| GTBP GT Biopharma Inc. | D- | 36/100 | — | — | -35.0% | -5.00% | $11.0M | /gtbp-vs-lsta → |
| GDTC CytoMed Therapeutics Limited | D+ | 52/100 | — | — | — | +2.02% | $10.9M | /gdtc-vs-lsta → |
| ASBP Aspire-Lakewood Holdings Inc. | D- | 40/100 | — | -1.9% | -35.0% | -4.36% | $11.4M | /asbp-vs-lsta → |
| CLRB Cellectar Biosciences Inc. | E | 32/100 | — | — | -35.0% | -1.23% | $11.4M | /clrb-vs-lsta → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000320017In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lisata Therapeutics Inc. (LSTA) reported GAAP revenue of $170.0K (-83.0% vs. FY2024 revenue of $1.0M ) , GAAP net income of -$17.0M, operating cash flow of -$15.9M, and free cash flow of -$16.0M (+17.5% YoY). On the balance sheet, LSTA closed FY2025 with $17.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $170.0K | -$17.0M | -$15.9M | -$16.0M | $17.7M | — |
| FY2024 (FY) | 2024-12-31 | $1.0M | -$20.0M | -$19.4M | -$19.4M | $35.0M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$21.0M | -$20.0M | -$20.0M | — | — |
3. LSTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs LSTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Lisata Therapeutics Inc. (NASDAQ: LSTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.02 (+0.99% 1D, market cap $11.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, LSTA ranks #849 in composite RQD confidence.
How does LSTA compare to GTBP and GDTC in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LSTA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GTBP (GT Biopharma Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $11.0M) and GDTC (CytoMed Therapeutics Limited) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, LSTA leads on earnings multiple (N/A) while LSTA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for LSTA?
Per LSTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000320017), Lisata Therapeutics Inc. generated $170.0K in revenue (-83.0% YoY), -$17.0M in net income, and -$16.0M in free cash flow against $17.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is LSTA trading relative to its 50-day, 200-day, and 52-week technical levels?
LSTA last traded at $1.02 (+0.99% on volume of 60,779 shares), positioning the stock -25.55% below its 50-day simple moving average ($1.37) and -65.77% below its 200-day simple moving average ($2.98). Across its 52-week range of $0.96 to $5.07, LSTA sits at the 1.5% percentile with a 14-day RSI of 39.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.15).
LSTA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is LSTA stock moving today?
Why LSTA Stock advanced +0.99% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 29/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
LSTA — Lisata Therapeutics Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:51:36Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, LSTA carries an RQD Score of 29 and a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -35%; FCF yield 0%); Whale 13F Flow at 3/20 (institutional accumulation and options positioning); Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 7/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 8/20 (Altman Z 2.5; Piotroski F 3/9; Debt/Equity 0.5). Taken together, the pillars indicate weak cash generation, weak institutional and insider signals, and a balance sheet the rating classifies as forensically risky. For a prospective investor, the rating points to downside risk rather than a value or growth case. Upside would require a reversal in cash burn and a sustained change in institutional and insider behavior, neither of which the source data demonstrates.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.2M | $-18.2M | $-17.0M | N/A | $-16.0M | $16.0M | N/A |
| FY 2024 | $1.0M | $-22.4M | $-20.0M | N/A | $-19.4M | $16.2M | N/A |
| FY 2023 | $0.0M | $-25.7M | $-21.0M | N/A | $-20.0M | N/A | N/A |
Per the SEC financials, revenue declined from $1.0M in FY 2024 to $0.2M in FY 2025, while net losses narrowed from $-20.0M to $-17.0M across the same period. Per the market data, operating margin and net margin are each -60%, gross margin is 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 3/9, with a Debt/Equity ratio of 0.5. Reported cash was $16.0M in FY 2025, against negative free cash flow of $-16.0M in the same year.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts section, the most recent items include:
- A report that Lisata Therapeutics won a new US patent for a pancreatic cancer drug.
- A Stocktwits report on sentiment score, message volume, participation score, and buzz level.
- A Stock Titan report referencing an SEC filing dated Oct 19, 2026.
- A GlobeNewswire report announcing a new method-of-use patent.
- A Halper Sadeh LLC investigation headline referencing whether LSTA, among other companies, is obtaining fair deals for shareholders.
All items are tagged with a YELLOW light and a MARKET WIRE impact label. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE and no proprietary signals are present. The investigation headline is a risk watch item, though the source data does not describe its scope or any findings.
Open Questions
- What are the specific products, indications, and development stage behind the patent and pancreatic cancer headlines, and do they carry a revenue path?
- What is the scope and status of the Halper Sadeh LLC investigation, and does it involve a transaction affecting shareholders?
- What is the current cash runway given FY 2025 cash of $16.0M against FCF of $-16.0M?
- Why are debt, EPS, and EV/EBITDA recorded as N/A or not available, and what is the full capital structure?
- Who holds the shares, and what are the current 13F and insider positions?
LSTA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Lisata Therapeutics Inc. (LSTA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 17h ago
Lisata Therapeutics wins new US patent for pancreatic cancer drug Yahoo Finance report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stocktwits • 20h ago
Lisata Therapeutics Inc (LSTA) sentiment score, message volume, participation score and buzz level Stocktwits report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 23h ago
LISATA THERAPEUTICS, INC. SEC Filing (Oct 19, 2026) Stock Titan report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GlobeNewswire • 1d ago
Lisata Therapeutics Announces New Method of Use Patent GlobeNewswire report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Lisata Therapeutics, Inc. (LSTA) Stock Price, News, Quote & History Yahoo Finance report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Daily Tribune News • 1d ago
Halper Sadeh LLC is Investigating Whether BWIN, LSTA, ACVA are Obtaining Fair Deals for their Shareholders The Daily Tribune News report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Manila Times • 1d ago
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors The Manila Times report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GlobeNewswire • 1d ago
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly GlobeNewswire report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
LSTA Bull vs. Bear Conversation Board — What's Your Call at $1.02?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LSTA 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $0.89 (-11.9%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is LSTA (E • RQD 29/100) a Buy at $1.01?
Welcome to the LSTA (Lisata Therapeutics Inc.) Roar Pit. Current RQD Composite is 29/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $0.79 (-21.8%)
Spot @ $1.01 Pump the brakes on LSTA — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on LSTA, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Lisata Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH
🎯 Target: $1.21 (+19.8%)
Spot @ $1.01 LSTA cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on LSTA, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.01 (52-wk range $0.96 - $5.07), any beat on forward guidance forces shorts and underweight funds to chase.